Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 67, Issue 21, Pages 3621-3631Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-010-0488-2
Keywords
APE1/APEX1/REF-1; Abasic endonuclease; DNA damage; Base excision DNA repair; Inhibitor; Cancer treatment
Categories
Funding
- National Institute on Aging, NIH
- Molecular Libraries Initiative of the NIH Roadmap for Medical Research
- National Human Genome Research Institute, NIH
- [1 R03 MH086444-01]
Ask authors/readers for more resources
APE1 is a multifunctional protein that possesses several nuclease activities, including the ability to incise at apurinic/apyrimidinic (AP) sites in DNA or RNA, to excise 3'-blocking termini from DNA ends, and to cleave at certain oxidized base lesions in DNA. Pre-clinical and clinical data indicate a role for APE1 in the pathogenesis of cancer and in resistance to DNA-interactive drugs, particularly monofunctional alkylators and antimetabolites. In an effort to improve the efficacy of therapeutic compounds, such as temozolomide, groups have begun to develop high-throughput screening assays and to identify small molecule inhibitors against APE1 repair nuclease activities. It is envisioned that such inhibitors will be used in combinatorial treatment paradigms to enhance the efficacy of DNA-interactive drugs that introduce relevant cytotoxic DNA lesions. In this review, we summarize the current state of the efforts to design potent and selective inhibitors against APE1 AP site incision activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available